IRON Stock Cash Flow Statements

Disc Medicine Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Disc Medicine Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities
net income	-55,247,000	-34,085,000	-29,457,000	-26,599,000	-26,352,000	-26,949,000	-23,579,000	-14,122,000	-15,947,000	-22,781,000	-21,229,000	-3,277,000	-7,090,000	-15,231,000	-17,823,000	-18,551,000	-16,447,000	-19,048,000
adjustments to reconcile net income to net cash from operations:
depreciation and amortization	85,000	20,000	9,000	11,000	110,000	26,000	25,000	25,000	25,000	25,000
stock-based compensation	8,420,000	6,363,000	4,334,000	4,332,000	4,091,000	4,058,000	1,927,000	1,270,000	1,309,000	1,024,000
amortization/accretion of investment securities	-2,621,000	-2,527,000	-2,212,000
income from initial consolidation of variable interest entity
non-cash lease expense	117,000	112,000
non-cash interest expense	208,000	207,000										5,000	13,000	36,000	26,000	32,000	37,000	188,000
other non-cash items		15,000	15,000	-48,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	-681,000	-7,230,000	2,080,000	1,107,000	2,496,000	-4,112,000	-1,507,000	213,000	1,036,000	-908,000	29,000	1,542,000	211,000	-1,430,000	1,562,000	-826,000	-215,000	-3,057,000
accounts payable	-321,000	-1,277,000	4,395,000	-1,047,000	-669,000	-7,360,000	3,969,000	3,766,000	-726,000	-10,750,000	2,337,000	-478,000	-3,492,000	2,159,000	2,021,000	-501,000	-2,131,000	2,173,000
accrued external research and development expenses	42,000	280,000	-9,191,000	5,981,000
other accrued expenses	1,171,000	-3,689,000	2,328,000	1,483,000
operating lease liabilities	72,000	435,000	-110,000	-121,000	-189,000	-75,000	34,000	52,000	-64,000	-76,000
net cash from operating activities	-47,918,000	-41,376,000	-27,573,000	-17,361,000	-15,393,000	-33,599,000	-17,796,000	-7,476,000	-12,724,000	-35,466,000	-12,405,000	-4,011,000	-9,498,000	-16,338,000	-12,668,000	-16,097,000	-15,928,000	-15,007,000
capex	-36,000	-851,000	-449,000	8,000	3,000	-67,000	6,000	-45,000	-12,000	-21,000	0	0	0	0	-10,000	0	0	0
free cash flows	-47,954,000	-42,227,000	-28,022,000	-17,353,000	-15,390,000	-33,666,000	-17,790,000	-7,521,000	-12,736,000	-35,487,000	-12,405,000	-4,011,000	-9,498,000	-16,338,000	-12,678,000	-16,097,000	-15,928,000	-15,007,000
cash flows from investing activities
purchases of marketable securities	-58,626,000	-347,250,000	-72,777,000	-94,098,000
maturities of marketable securities	110,351,000	75,468,000	71,800,000
purchases of property and equipment	-36,000	-851,000	-449,000	8,000	3,000	-67,000	-3,000	-45,000	-12,000	-29,000
net cash from investing activities	51,689,000	-272,633,000	-1,426,000	-71,090,000	-219,749,000	-67,000	-3,000	-45,000	-12,000	-29,000					405,000
cash flows from financing activities
proceeds from sale of common stock in underwritten offering, net of issuance costs paid	0	234,003,000
proceeds from sale of pre-funded warrants in underwritten offering, net of issuance costs paid	0	9,386,000
proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid			0	0	-59,000	14,849,000				14,605,000
proceeds from stock option exercises	892,000	575,000	1,202,000	401,000	567,000	806,000	806,000	618,000	1,076,000	222,000
contributions from employee stock purchase plan	0	287,000	0	196,000	0	245,000
net cash from financing activities	892,000	244,251,000	28,797,000	426,000	173,191,000	15,900,000	7,758,000	460,000	153,855,000	77,306,000	154,344,000	-2,911,000	-1,230,000	-1,225,000	-1,179,000	-1,250,000	-1,581,000	195,490,000
net decrease in cash, cash equivalents and restricted cash	4,663,000	-69,758,000
cash, cash equivalents and restricted cash, beginning of period	0	192,672,000	0	0	0	360,616,000	0	0	0	194,788,000
cash, cash equivalents and restricted cash, end of period	4,663,000	122,914,000	-202,000	-88,025,000	-61,951,000	342,850,000	-10,041,000	-7,061,000	141,119,000	236,599,000
supplemental cash flow information
cash paid for interest	709,000	698,000										35,000	36,000	47,000	59,000	104,000	84,000	60,000
supplemental disclosure of non-cash activities
deferred issuance costs related to underwritten offering included in accounts payable and accrued expenses		225,000
proceeds from issuance of long-term debt, net of issuance costs paid
payment of debt issuance costs
proceeds from sale of common stock in offerings, net of issuance costs paid			0	-171,000			6,952,000	-100,000
proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid							0	-58,000
net increase in cash, cash equivalents and restricted cash			-202,000	-88,025,000	-61,951,000	-17,766,000	-10,041,000	-7,061,000	141,119,000	41,811,000
change in fair value of contingent value right liability								0
noncash lease expense				36,000	146,000	142,000	110,000	46,000	50,000	84,000
cash paid for income taxes				4,000			34,000
right-of-use assets obtained in exchange for new operating lease liabilities							0	0
net increase in right-of-use assets related to lease modifications and reassessment events
net increase in operating lease liabilities related to lease modifications and reassessment events
deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses							10,000	-343,000
amortization/ accretion of investment securities
cash flow from investing activities
cash flow from financing activities
net decrease in right-of-use assets related to lease modifications and reassessment events
net decrease in operating lease liabilities due to lease modifications and reassessment events
receivable related to deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in other current assets
accrued expenses						671,000	2,725,000	1,274,000	93,000	-2,084,000
purchases of property and equipment included in accounts payable and accrued expenses							9,000			8,000
receivable for proceeds from stock option exercises included in other current assets										845,000
change in fair value of derivative liability
other assets											25,000	6,000	13,000	20,000	-5,000	327,000	-334,000	-225,000
proceeds from the issuance of common stock in pre-closing financing
cash acquired in connection with the reverse recapitalization
payment of reverse recapitalization transaction costs
settlement of derivative liability upon issuance of common stock to roche
decrease in right-of-use assets related to lease modifications
decrease in operating lease liabilities due to lease modifications
decrease in right-of-use assets related to lease modification
decrease in operating lease liabilities due to lease modification
proceeds from sale of common stock in registered direct offering, net of issuance costs paid										34,217,000
proceeds from sale of pre-funded warrants in registered direct offering, net of issuance costs paid										28,262,000
deferred issuance costs on sale of common stock in registered direct offering included in accounts payable and accrued expenses										69,000
deferred issuance costs on sale of pre-funded warrants in registered direct offering included in accounts payable and accrued expenses										56,000
deferred issuance costs on sale of common stock in at-the-market offerings included in accounts payable and accrued expenses										97,000
deferred issuance costs on equity financing included in accounts payable and accrued expenses
noncash license expense
proceeds from issuance of convertible preferred stock, net of issuance costs
deferred issuance costs on series b convertible preferred stock in accounts payable and accruals
deferred offering costs included in accounts payable and accruals at end of period
cash flows from operating activities:
adjustments to reconcile net income to net cash from operating activities:
depreciation expense															46,000	58,000	62,000	65,000
stock-based compensation expense												941,000	2,356,000	1,976,000	1,673,000	1,659,000	2,862,000	1,593,000
loss on conversion of convertible notes															0	0	0	711,000
accretion of discount on convertible notes															0	0	0	1,600,000
deferred offering or transaction costs
accrued expenses and other current liabilities												-1,581,000	-1,509,000	-3,868,000	135,000	1,705,000	238,000	-348,000
cash flows from investing activities:
purchase of property and equipment															-10,000
cash flows from financing activities:
proceeds from business combination															0	0	-437,000	196,319,000
proceeds from exercise of stock options												6,000	9,000	25,000	71,000	0	106,000	4,000
proceeds from sale of stock under employee stock purchase plan												0
principal payments on term loan												-2,917,000	-1,250,000	-1,250,000	-1,250,000	-1,250,000	-1,250,000	-833,000
increase in cash, cash equivalents and restricted cash												-6,922,000	-10,728,000	-17,563,000	-13,442,000	-17,408,000	-17,509,000	180,483,000
cash, cash equivalents and restricted cash at beginning of period												0	0	136,950,000		0	0	4,826,000
cash, cash equivalents and restricted cash at end of period												-6,922,000	-10,728,000	119,387,000		-17,408,000	-17,509,000	185,309,000
supplemental disclosure
noncash financing activities
proceeds from exercise of stock options included in other current assets															60,000
conversion of convertible notes to series b preferred stock															0	0	0	14,515,000
exercise of warrants															0	0	0	76,000
property and equipment purchases included in accounts payable and accrued expenses																-52,000
deferred offering costs															0	0	0	1,341,000
cash - fsdc trust account and cash													0	121,782,000			0	121,782,000
cash - pipe financing													0	95,060,000			0	95,060,000
less: equity issuance costs and other costs paid													0	-20,960,000
net proceeds from the business combination													0	195,882,000			0	195,882,000
unpaid issuance costs in accounts payable and accrued expenses and other current liabilities																		437,000
gain on the sale of property and equipment
change in fair value of warrant liability
proceeds from the sale of property and equipment
proceeds from sale of series b convertible preferred stock
proceeds from convertible notes
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
noncash investing and financing activities
proceeds from the sale of property and equipment included in other current assets
discount on convertible notes
deferred offering costs included in accounts payable and accrued expenses and other current liabilities
less: equity issuance costs and other costs paid prior to june 30, 2021
less: underwriting fees and other issuance costs paid prior to march 31, 2021																		-20,523,000
proceeds from business combination, net of issuance costs paid per the cash flows from financing activities																		196,319,000
less: other issuance costs included in accounts payable and accrued expenses and other current liabilities																		-437,000

We provide you with 20 years of cash flow statements for Disc Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Disc Medicine stock. Explore the full financial landscape of Disc Medicine stock with our expertly curated income statements.

The information provided in this report about Disc Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.